日本語フィールド
著者：○Sogawa R, Matsuoka A, Murakawa-Hirachi T, Kikkawa N, Kamo M, Tobita S, Shinada K, Mizoguchi Y, Monji A, Sakamoto Y, Shimanoe C題名：Effects of anti-ulcer drugs on delirium in trauma patients発表情報：Gen Hosp Psychiatry 巻: 80 ページ: 43-47キーワード：Delirium; Histamine-2 receptor antagonist; Proton pump inhibitor概要：Objective: Histamine-2 receptor antagonists (H2RAs) may induce a higher risk of developing delirium than proton pump inhibitors (PPIs), but current evidence is insufficient. Therefore, this study aimed to investigate whether anti-ulcer drugs increase delirium risk.
Method: Data were obtained from the medical records of patients admitted to a hospital due to trauma. We compared the incidence of delirium in patients who received H2RAs and PPIs with that in patients who received no anti-ulcer drugs.
Results: A total of 150, 158, and 238 patients received H2RAs, PPIs, and no anti-ulcer drugs, respectively. Delirium incidence was significantly higher in patients who received H2RAs (34.0%) and PPIs (44.9%) than in those who did not receive anti-ulcer drugs (22.3%). Even after adjustment for possible confounding factors, the association between H2RAs and delirium remained (adjusted OR 1.78; 95% CI 1.04-3.05), but that between PPIs and delirium was attenuated (adjusted OR 1.25; 95% CI 0.71-2.23).
Conclusions: Our results show that H2RAs are associated with delirium risk. We replicated findings of a previous data-driven study. Clinicians need to consider the effect of delirium in anti-ulcer drug selection.抄録：英語フィールド
Author：○Sogawa R, Matsuoka A, Murakawa-Hirachi T, Kikkawa N, Kamo M, Tobita S, Shinada K, Mizoguchi Y, Monji A, Sakamoto Y, Shimanoe CTitle：Effects of anti-ulcer drugs on delirium in trauma patientsAnnouncement information:Gen Hosp Psychiatry Vol: 80 Page: 43-47Keyword：Delirium; Histamine-2 receptor antagonist; Proton pump inhibitorAn abstract：Objective: Histamine-2 receptor antagonists (H2RAs) may induce a higher risk of developing delirium than proton pump inhibitors (PPIs), but current evidence is insufficient. Therefore, this study aimed to investigate whether anti-ulcer drugs increase delirium risk.
Method: Data were obtained from the medical records of patients admitted to a hospital due to trauma. We compared the incidence of delirium in patients who received H2RAs and PPIs with that in patients who received no anti-ulcer drugs.
Results: A total of 150, 158, and 238 patients received H2RAs, PPIs, and no anti-ulcer drugs, respectively. Delirium incidence was significantly higher in patients who received H2RAs (34.0%) and PPIs (44.9%) than in those who did not receive anti-ulcer drugs (22.3%). Even after adjustment for possible confounding factors, the association between H2RAs and delirium remained (adjusted OR 1.78; 95% CI 1.04-3.05), but that between PPIs and delirium was attenuated (adjusted OR 1.25; 95% CI 0.71-2.23).
Conclusions: Our results show that H2RAs are associated with delirium risk. We replicated findings of a previous data-driven study. Clinicians need to consider the effect of delirium in anti-ulcer drug selection.